11/7
08:42 am
ipsey
Ipsen to present two late-breaking sessions at AASLD on new PBC data supporting IQIRVO®’s long-term efficacy, safety and mechanistic insights in fatigue
Neutral
Report
Ipsen to present two late-breaking sessions at AASLD on new PBC data supporting IQIRVO®’s long-term efficacy, safety and mechanistic insights in fatigue
11/3
06:11 pm
ipsey
IPSEN (OTCMKTS:IPSEY) had its "buy" rating reaffirmed by analysts at Deutsche Bank Aktiengesellschaft.
Medium
Report
IPSEN (OTCMKTS:IPSEY) had its "buy" rating reaffirmed by analysts at Deutsche Bank Aktiengesellschaft.
10/23
07:32 am
ipsey
Ipsen Launches Educational Initiative to Support Teens and Young Adults Moving From Pediatric to Adult Healthcare
Low
Report
Ipsen Launches Educational Initiative to Support Teens and Young Adults Moving From Pediatric to Adult Healthcare
10/22
04:00 am
ipsey
EQT Life Sciences' ImCheck Therapeutics to be acquired by Ipsen in a transaction valued at up to EUR 1 billion
Neutral
Report
EQT Life Sciences' ImCheck Therapeutics to be acquired by Ipsen in a transaction valued at up to EUR 1 billion
10/22
01:05 am
ipsey
Ipsen delivers strong sales in the first nine months of 2025 and further upgrades its full-year guidance
Neutral
Report
Ipsen delivers strong sales in the first nine months of 2025 and further upgrades its full-year guidance
10/22
01:00 am
ipsey
Ipsen to acquire ImCheck Therapeutics, expanding its leadership in oncology, strengthening its pipeline
Neutral
Report
Ipsen to acquire ImCheck Therapeutics, expanding its leadership in oncology, strengthening its pipeline
9/22
01:00 am
ipsey
Ipsen’s LANTIC Phase II in aesthetics delivers a first-in-class, differentiated long-acting clinical profile for IPN10200, enabling the initiation of Phase III
Neutral
Report
Ipsen’s LANTIC Phase II in aesthetics delivers a first-in-class, differentiated long-acting clinical profile for IPN10200, enabling the initiation of Phase III
9/19
07:59 am
ipsey
Bylvay® (odevixibat) approved in Japan for rare liver disease PFIC
Low
Report
Bylvay® (odevixibat) approved in Japan for rare liver disease PFIC